Allergy Therapeutics PLC
LSE:AGY
Allergy Therapeutics PLC
LSE:AGY
Price:
2.875 GBX
Market Closed
Updated:
May 4, 2024
Allergy Therapeutics PLC
Cash from Financing Activities
|
Allergy Therapeutics PLC
Cash from Financing Activities Peer Comparison
Comparables:
GSK
AZN
INDV
HIK
DPH
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Cash from Financing Activities
£34.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Cash from Financing Activities
-£5.6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
2%
|
CAGR 10-Years
1%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Cash from Financing Activities
-$6.6B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-8%
|
|
|
Indivior PLC
LSE:INDV
|
Cash from Financing Activities
-$46m
|
CAGR 3-Years
-66%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Cash from Financing Activities
-$337m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-4%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Cash from Financing Activities
£316.5m
|
CAGR 3-Years
39%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
See Also
What is Allergy Therapeutics PLC's Cash from Financing Activities?
Cash from Financing Activities
34.1m
GBP
34.1m
GBP
Based on the financial report for Dec 31, 2023, Allergy Therapeutics PLC's Cash from Financing Activities amounts to 34.1m GBP.
What is Allergy Therapeutics PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
29%
29%
Over the last year, the Cash from Financing Activities growth was 854%.
You don't have any saved screeners yet
